Research Article

Compound phenotype of osteogenesis imperfecta and Ehlers–Danlos syndrome caused by combined mutations in \( \text{COL1A1} \) and \( \text{COL5A1} \)

Zejia Lin*, Jican Zeng* and Xinjia Wang

The Second Hospital, Shantou University Medical College, Shantou, Guangdong 515041, China

Correspondence: Xinjia Wang (xj.wang2000@163.com)

Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with a broad clinical spectrum that can overlap with Ehlers–Danlos syndrome (EDS). To date, patients with both OI and EDS have rarely been reported. In the present study, we investigated a family with four members, one healthy individual, one displaying OI only, and two displaying the compound phenotype of OI and EDS, and identified the pathogenic mutations. Whole exome sequencing was applied to the proband and her brother. To verify that the mutations were responsible for the pathogenesis, conventional Sanger sequencing was performed for all members of the family. We identified a known \( \text{COL1A1} \) (encoding collagen type I \( \alpha_1 \) chain) mutation (c.2010delT, \( \text{p.Gly671Alafs}^*95 \)) in all three patients (the proband, her brother, and her mother) in this family, but also a novel heterozygous \( \text{COL5A1} \) (encoding collagen type V \( \alpha_1 \) chain) mutation (c.5335A>G, \( \text{p.N1779D} \)) in the region encoding the C-terminal propeptide domain in the proband and her mother, who both had the compound phenotype of OI and EDS. The results of the present study suggested that the proband and her mother presented with the compound OI–EDS phenotype caused by pathogenic mutations in \( \text{COL5A1} \) and \( \text{COL1A1} \).

Introduction

Osteogenesis imperfecta (OI), or brittle bone disease, is a clinically and genetically heterogeneous disorder that mainly results in osteopenia, bone fragility, blue sclerae, dentinogenesis imperfecta, and hearing loss [1]. OI can be classified into types I–IV, and approximately 85–90% of individuals with OI have a mutation in either collagen type I \( \alpha_1 \) chain (\( \text{COL1A1} \)) or collagen type I \( \alpha_2 \) chain (\( \text{COL1A2} \)). Type I collagen is the most abundant protein in bone, skin, and the tendon extracellular matrix [2]. The OI Mutation Consortium, an international collaboration of many laboratories that identify OI mutations, has found that 80% of \( \text{COL1A1/2} \) mutations give rise to substitution of glycine residues in the type I collagen chain, and the remaining 20% of mutations result in abnormalities of mRNA splicing [3]. Mutations in the gene coding type I procollagen produce a range of disorders, including autosomal dominant OI and the rare arthrochalasis subtype of Ehlers–Danlos syndrome (EDS) [4–6]. EDS is a connective tissue disorder that is characterized by abnormal wound healing, easy bruising, atrophic scarring, and joint hypermobility [7]. Classic-type EDS (cEDS) occurs because of a \( \text{COL5A1/2} \) (encoding collagen type V \( \alpha_1 \) or 2 chain) mutation and is inherited in an autosomal dominant manner. It is estimated that approximately 50% of patients with cEDS harbor a \( \text{COL5A1} \) or \( \text{COL5A2} \) mutation [7].

In the present study, we report a rare family presenting with a compound phenotype of OI and EDS, such as multiple fractures, blue sclerae, atrophic scarring, easy bruising, and joint hypermobility. To understand the basis of the disorder, provide a theoretical foundation for genetic counseling, and to determine whether patients simultaneously harbor pathogenic mutations in genes associated with OI and EDS, whole exome...
sequencing was performed. We identified a \textit{COL1A1} mutation known to be responsible for OI, and a novel C-propeptide domain mutation in \textit{COL5A1}. To the best of our knowledge, this is the first report of patients with compound phenotypes of OI and EDS that harbor both \textit{COL1A1} and \textit{COL5A1} mutations.

**Materials and methods**

The study was approved by the Ethics Committee of the Second Hospital, Shantou University Medical College. Written informed consent was obtained from each individual for their DNA to be used for research purposes.

**DNA extraction**

DNA extraction was performed using a QIAamp DNA Mini Kit (Cat. No. 51104, Qiagen, Hilden, Germany) according to the manufacturer's protocol. Genomic DNA was obtained from peripheral blood samples from the family members (Figure 1), including the proband (III-1), her brother (III-2), and their parents (II-1, II-2).

**Whole exome sequencing**

Library preparation and sequencing

Whole exome sequencing was performed for the two affected children (III-1, III-2) at the Beijing Novogene Bioinformatics Technology Co., Ltd (Beijing, China). Exome sequences were enriched using an Agilent liquid capture system (Agilent SureSelect Human All Exon V6; Agilent Technologies, Santa Clara, CA, U.S.A.) according to the manufacturer's protocol. First, genomic DNA was randomly fragmented to an average size of 180–280 bp using a Covaris S220 sonicator (Covaris, Brighton, U.K.). Second, the DNA fragments were end-repaired and phosphorylated, followed by A-tailing and ligation at the 3' ends with paired-end adaptors (Illumina, San Diego, CA, U.S.A.) with a single 'T' base overhang, and purified using AMPure SPRI beads from Agencourt (Azincourt, France). Then, the size distribution and concentration of the libraries were determined using an Agilent 2100 Bioanalyzer and qualified by using real-time PCR. The DNA libraries were then sequenced on an IlluminaHiSeq 4000 sequencer for paired-end 150 bp reads at Beijing Novogene Bioinformatics Technology Co., Ltd. The raw data were saved as a FASTQ (fq) format file.

**Selection of valid sequencing data**

Initially, reads with adapter contamination were filtered out. Then, reads that contained more than 10% uncertain nucleotides and paired reads with single reads of low quality (Phred-like quality score (Q score) <5) were also discarded.

**Sequencing data mapping to reference sequences and variant calling**

The valid sequencing data were mapped to the reference human genome (UCSC hg19) using Burrows–Wheeler Aligner (BWA) software (version 0.7.8; https://sourceforge.net/p/bio-bwa/mailman/message/32169236/). Subsequently, Samtools software 1.0 (also from Sourceforge) was used to sort the BAM files. Picard (http://broadinstitute.github.io/picard) was then employed to identify and delete duplicates. Finally, Samtool smapleup and BCF tools were used to perform variant calling and identify single nucleotide polymorphisms (SNPs) and indels, which were stored as a variant call format (VCF) file.
Table 1  Clinical features of all members of the proband's family

| Family | Proband (III1) | III2 | II1 | II2 |
|--------|----------------|------|-----|-----|
| Age (years) | 18 | 14 | 40 | 42 |
| OI phenotype | + | + | + | - |
| Dentinogenesis | - | - | - | - |
| Blue sclerae | + | + | + | - |
| Hearing loss | - | - | - | - |
| EDS phenotype | + | - | + | - |
| Joint laxity | + | - | + | - |
| Easy bruising | + | - | + | - |
| Atrophic scarring | + | - | + | - |
| Ligament rupture | + | - | + | - |
| Other symptoms | + | + | + | - |

Functional annotation and variant filter

ANNOVAR (http://annovar.openbioinformatics.org/en/latest/) was used to annotate the VCF file. The variant position, variant type, conservation prediction, and other information were obtained at this step using a variety of databases, such as dbSNP, 1000 Genome, ExAC, CADD, and HGMD. Gene transcript annotation databases, such as Consensus CDS, RefSeq, Ensembl, and UCSC, were also applied for annotation to identify amino acid alterations. Variants were filtered with a Minor Allele Frequency (MAF) > 0.1% in the 1000 Genomes database (1000 Genomes Project Consortium). Then, synonymous single nucleotide variants (SNVs) were discarded and the retained non-synonymous SNVs were submitted to PolyPhen-2, SIFT, MutationTaster, and CADD for functional prediction. A non-synonymous SNV was retained if at least two out of the four software programs showed it to be 'not benign'. Finally, we focused on genes known to be associated with OI and EDS.

Sanger sequencing of candidate variants

To confirm the candidate variants identified by whole exome sequencing, Sanger sequencing was performed for all members of the family displaying complicated phenotypes of OI and EDS. Primers were designed by using Premier Primer 5 software (PREMIER Biosoft International, Palo Alto, CA, U.S.A.). We used genomic DNA to amplify the region of the respective variant using Takara ExTaq® Hot Start Version (RR006A; Takara, Shiga, Japan). The Beijing Genomics Institute performed the purification of the PCR-amplified DNA and Sanger sequencing (using an ABI 3730XL sequencer).

Evolutionary conservation analysis

To evaluate the evolutionary conservation of the site of the novel COL5A1 mutation, the protein sequences of COL5A1 from eight animal species, including human, rhesus, mouse, elephant, opossum, chicken, Xenopus laevis, and zebrafish, were aligned using ClustalW embedded in MEGA7 (https://www.megasoftware.net/).

Results

Clinical characteristics of a Chinese family with OI

This OI family had two patients with a compound OI and EDS phenotype, a patient with only OI, and a healthy individual (Figure 1). In this family, the female proband (III-1), who was 18 years old, appeared to be healthy before the age of 12 years. Thereafter, fractures of long bones occurred three times, and her knee ligament ruptured when she was involved in a car accident at 17 years old. She also presented with blue sclerae, atrophic scarring, joint hypermobility, prominent ears, and easy bruising (Table 1 and Figure 2).

Similarly, the proband’s mother (II-1), 40 years old, not only presented with multiple fractures of long bones and blue sclerae, but also suffered from easy bruising after minor trauma, atrophic scarring, joint hypermobility, joint laxity, and prominent ears (Table 1). The proband’s brother (III-2) was 14 years old, and showed multiple fractures of long bones and blue sclerae, but did not have easy bruising, atrophic scarring, joint hypermobility, or joint laxity.
Figure 2. Radiographic images, magnetic resonance imaging, and photographs of the findings in proband III-1
Radiographic images: (A) right tibia fracture, (B) right femoral fracture. (C, D) Magnetic resonance imaging (MRI) of the posterior cruciate ligament rupture in the right knee-joint. Photographs of joint hypermobility (E, F), atrophic scarring (G).

In this family, the proband's father (II-2), 42 years old, was healthy (i.e., presented no symptoms of OI or EDS); all patients had normal mental development and normal hearing (Table 1).

Identification of mutations
To identify the causative mutations of OI in the family, whole exome sequencing was performed on proband (III-1) and her brother (III-2). The total raw data comprised 27.35 GB for the proband and her brother. An average of 98.2% of the reads had a Q score greater than 20, and 95.5% of the reads had a Q score greater than 30. Quality control indicated that 99.4% of the raw data were valid sequencing data. For III-1 and III-2, the average sequencing depth on target was 165.5× and 129.4×, respectively, and the fractions of the target covering a depth of at least 10× were 99.5 and 99.6%, respectively.

In this family, we not only found a heterozygous mutation (c.2010delT, p.Gly671Alafs*95) in COL1A1 in III-1 and III-2, but also observed a novel heterozygous mutation of COL5A1 (c.5335A>G). To validate the results of whole exome sequencing, Sanger sequencing was performed on the entire family. The COL1A1 mutation (c.2010delT) was identified in all patients (II-1, III-1, and III-2) (Figure 3A), and the COL5A1 mutation (c.5335A>G) was only identified in the proband (III-1) and her mother (II-1) (Figure 3B). Neither mutation was found in the father (II-2) (Figure 3A,B). COL5A1 (c.5335A>G) resulted in the substitution of an asparagine residue in the C-propeptide domain in the proband (III-1) (Figure 3C). No potential variants were found in 18 other genes (BMP1, COL1A2, CREB3L1, CRTAP, FKBP10, IFITM5, MBTPS2, P3H1, P4HB, PLOD2, PLS3, PPIB, SERPINF1, SERPINF2, SPARC, TMEM38B, WNT1, and SEC24D) associated with OI or in 10 other genes (ADAMTS2, B3GALT6, B4GALT7, COL3A1, COL5A2, DSE, FKBP14, PLOD1, PLOD3, and TNXB) associated with EDS. The COL5A1 mutation was predicted by SIFT, Mutation Taster, CADD, and Polyphen2 to be deleterious, disease causing, damaging, and benign, respectively. This mutation was classified as uncertain significance and likely benign in ClinVar database. Comparison of the COL5A1 protein sequences from related animal species indicates that this COL5A1 mutation occurred at an evolutionarily conserved site (Figure 3D).

Discussion
We characterized three patients with OI and a healthy individual from the same Chinese family. Among them, two patients had a compound OI and EDS phenotype, manifesting as multiple fractures, blue sclerae, atrophic scarring, easy bruising, and joint hypermobility. To understand cause of the phenotypic variability, we performed whole exome sequencing and identified a COL1A1 mutation and a novel COL5A1 mutation in the patients with the compound OI/EDS phenotype.

Type I collagen is the most abundant organic component of bone, skin, and tendon extracellular matrix [2]. To date, more than 1000 COL1A1/2 mutations have been identified in patients with OI. OI caused by COL1A1/2 mutations is classified into two types. The first type involves the substitution of a glycine within the Gly-x-y triplet domain of
Figure 3. **COL1A1** and **COL5A1** variants, structure of the collagen type V α-chain, and evolutionary conservation of the **COL5A1** mutated site

(A) Sequences of the genomic region mutated in **COL1A1**. The mutation in the mother (II-1), proband (III-1), and brother (III-2) are marked by black arrows. (B) Sequences of the mutation in **COL5A1**. The mutation in the mother (II-1) and proband (III-1) are marked by black arrows. (C) Structure of collagen type V α-chain: purple indicates the site of the mutation (c.5335A>G, P. N1779D) in the C-terminal propeptide. (D) The site of the **COL5A1** mutation is evolutionarily conserved. The mutation is marked by a red arrow.

the triple helix, which can give rise to the abnormal synthesis of collagen fibrils. The second type of mutation takes the form of frameshift, nonsense, and splice-site mutations, which can result in haploinsufficiency [1,8].

In this family, the patient (proband (III-1), her mother (II-1), and her brother (III-2)) have the heterozygous **COL1A1** mutation (c.2010delT) and the **COL5A1** mutation in proband (III-1) and her brother (III-2) were inherited from their affected mother. This frameshift mutation (c.2010delT) has been reported in type I/IV OI [9,10], and is...
predicted to cause premature termination at codon 94 [10], which could result in haploinsufficiency. Thus, our results further support the view that the COL1A1 mutation (c.2010delT) can result in OI.

The proband's brother harbors only the c.2010delT COL1A1 mutation, and only has the clinical symptoms of OI. However, the phenotypes of the proband (III-1) and her mother are different from those of her brother. Interestingly, we identified an additional heterozygous gene mutation in the region of COL5A1 encoding the C-terminal propeptide domain, which correlates with the EDS phenotype, and the COL5A1 mutation in proband (III-1) is inherited from her affected mother. This finding may explain why the phenotypes of proband III-1 and her mother are different from those of proband’s brother. The molecular basis of cEDS is essentially a deficiency of type V collagen, which is a quantitatively minor fibrillar collagen that is widely distributed in a variety of connective tissues [11]. The major variant of type V collagen is a heterotrimer that is composed of two pro-α1 (V) chains and a single pro-α2 (V) chain, which are encoded by the COL5A1 and COL5A2 genes, respectively [12,13].

The COL5A1 gene encodes the α1 chain of type V collagen, which is a minor fibrillar collagen found in ligament and tendons, as well as other tissues [14]. Mutations in the COL5A1 C-terminal propeptide domain can cause ‘functional’ haploinsufficiency of type V collagen [15,16], either because of inefficient trafficking of the mutant protein through the endoplasmic reticulum [17] or the impaired incorporation of the mutant α1 chain into type V collagen, and is an important factor in the pathogenesis of cEDS [16,18]. The mutant α1 chain of type V collagen also plays a negative role by disrupting the interactions with other ECM components, which can be observed in patients with COL5A1 mutations in the C-terminal propeptide domain [19].

Type I and V collagens are the two main components of ligaments. Thus, mutations in COL1A1 and COL5A1 are potential risk factors for ligament rupture [20], as displayed by our proband. The action of an external force could make the ligament easier to rupture. The proband experienced ligament rupture caused by trauma resulting from a car accident, not from a spontaneous rupture. In addition, the proband’s mother had no history of trauma, and had not suffered ligament rupture. The type V collagen plays a central role in collagen fibrillogenesis and co-assembles with type I collagen to form heterotypic fibrils [12,23]. Type V collagen intercalates into the core of type I collagen fibrils, where it is involved in the organization and regulation of type I collagen fibril diameter [21]. In col5a1<sup>−/−</sup> mice, tendons have larger diameter fibrils, resulting in an irregular shape [22]. Irregularly shaped fibrils generate a diminished dynamic mechanical response of col5a1<sup>−/−</sup> tendons [22], and COL5A1 mutations give rise to structural tendon pathology and low tendon stiffness responsible for joint hypermobility [23]. The COL5A1 mutation (c.5335A>G) results in a change from aspartagine to aspartic acid. However, interpreting the COL5A1 mutation as disease causing without some functional studies is a limitation of our report. Mutations described previously in the C-propeptide domain of the COL5A1 gene have involved Cysteine residues. Cysteine residues form disulfide bonds between collagen chains and changing Cysteine to another amino acid interferes with the ability of the individual collagen molecule to assemble into a trimer [18]. The effect of a mutation involving asparagine to aspartic acid change in the C-propeptide domain of COL5A1 has not been reported. However, the c.5335A>G mutation in COL5A1 was predicted by SIFT, Mutation Taster and CADD, respectively, to be deleterious, disease causing and damaging, indicating that this mutation could be potentially causative of disease, consistent with a role in EDS. In support of this, the site of this COL5A1 mutation is evolutionarily conserved, suggesting that it has an important biological function. Other known and potential pathogenic variants for OI and EDS were not identified by whole exome sequencing in this family. In addition, the COL5A1 mutation was not found in the proband’s brother, who did not display the clinical symptoms of EDS. Finally, mutations in TNXB, which has been associated with EDS and COL1A1 can give rise to overlapping phenotypes of OI and EDS [24]. Therefore, we speculated that the combined mutations in COL1A1 and the COL5A1 C-terminal propeptide domain could result in the hybrid EDS-OI phenotype of the proband III-1 and her mother, both of whom exclusively carry the COL5A1 (c.5335A>G) mutation within the family. Further functional studies with a larger sample size are needed to confirm the results.

In conclusion, in a family with OI, we identified a COL1A1 mutation known to be responsible for OI, and further identified a novel second mutation in the COL5A1 C-terminal propeptide domain in patients with OI and EDS. These results suggested that a combination of COL5A1 and COL1A1 mutations might lead to compound phenotypes of OI and EDS. To the best of our knowledge, this is the first report showing that members of a family with both COL1A1 and COL5A1 mutations present with a hybrid phenotype of OI and EDS. In addition, our results support the conclusion that that COL1A1 (c.2010delT) can result in OI. Whole exome sequencing can help us to understand the basis of diseases with compound phenotypes and provide a theoretical foundation for genetic counseling.

Acknowledgments
The authors wish to thank the family for their participation in the present study.

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Funding
This work was supported by the Shantou University Medical College Clinical Research Enhancement Initiative [grant number 2014047]; and the Shantou City Science and Technology Plan Major Project, Guangdong Province, China [grant number 20140305].

Author Contribution
Xinjia Wang was responsible for study design, data analysis, data interpretation, preparation of the manuscript, literature analysis, and funds collection. Zejia Lin and Jican Zeng were responsible for the study design, data collection, data analysis, data interpretation, preparation of the manuscript, and literature analysis. All authors read and approved the final manuscript.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
EDS, classic-type EDS; COL1A1, collagen type I α 1 chain; COL1A2, collagen type I α 2 chain; COL5A1, collagen type V α 1 chain; EDS, Ehlers–Danlos syndrome; OI, osteogenesis imperfecta; SNP, single nucleotide polymorphism; SNV, single nucleotide variant; VCF, variant call format.

References
1. Marini, J.C., Forlino, A., Cabral, W.A., Barnes, A.M., San Antonio, J.D., Milgrom, S. et al. (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. *Hum. Mutat.* 28, 209–221, https://doi.org/10.1002/humu.20429
2. Forlino, A. and Marini, J.C. (2016) Osteogenesis imperfect. *Lancet* 16, 1657–1671, https://doi.org/10.1016/S0140-6736(15)00728-X
3. Glorieux, F.H. (2008) Osteogenesis imperfecta. *Best Pract. Res. Clin. Rheumatol.* 22, 85–100, https://doi.org/10.1016/j.berrh.2007.12.012
4. Calzavara-Pinton, P. and Ritelli, M. (2017) Delineation of Ehlers–Danlos syndrome phenotype due to the mutation (c.934C>T:p.Arg312Cys) in COL1A1: report on a three-generation family without cardiovascular events, and literature review. *Am. J. Med. Genet.* 173, 524–530
5. Byers, P.H., Ducic, M., Atkinson, M., Robinow, M., Smith, L.T., Krane, S.M. et al. (1997) Ehlers–Danlos syndrome type VIIA and VIIB result from signal peptide mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I collagen. *Am. J. Med. Genet.* 72, 94–105, https://doi.org/10.1002/ASDI.1096-8628(19970103)72:1%3C:aid-AID-AMG629%3E3.0.CO;2-0
6. Symoens, S., Steyaert, W., Demuynck, L., De Paeppe, A., Dierich, K.E., Malfait, F. et al. (2017) Tissue-specific mosaicism for a lethal osteogenesis imperfect COL1A1 mutation causes mild OI/EDS overlap syndrome. *Am. J. Med. Genet.* 173, 1047–1050, https://doi.org/10.1002/ajmg.a.38135
7. Malfait, F., Wenstrup, R.J. and De Paeppe, A. (2010) Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. *Genet. Med.* 12, 597–605, https://doi.org/10.1097/GIM.0b013e3181e6d412
8. Räuch, F., Lalic, L., Roughley, P. and Glorieux, F.H. (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. *J. Bone Miner. Res.* 25, 1367–1374
9. Ward, L.M., Lalic, L., Roughley, P.J. and Glorieux, F.H. (2001) Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I–V. *Hum. Mutat.* 17, 434, https://doi.org/10.1002/humu.1124
10. Balasubramanian, M., Sobey, G.J., Wagner, B.E., Peres, L.C., Bowen, J., Bexon, J. et al. (2016) Osteogenesisimperfecta: ultrastructural and histological findings on skin revealing novel insights into genotype-phenotype correlation. *Ultrastruct. Pathol.* 40, 71–76, https://doi.org/10.3109/01913323.2016.1140253
11. Hildebrand, K.A., Frank, C.B. and Hart, D.A. (2004) Gene intervention in ligament and tendon: current status, challenges, future directions. *Gene Ther.* 11, 368–378, https://doi.org/10.1038/sj.gt.3302198
12. Mayer, K., Kennerknecht, I. and Steinmann, B. (2013) Clinical utility gene card for: Ehlers-Danlos syndrome types I-VII and variants - update 2012. *Eur. J. Hum. Genet.* 21, https://doi.org/10.1038/ejhg.2012.162
13. Fichard, A., Tillet, E., Delacoux, F., Garrone, R. and Ruggiero, F. (1997) Human recombinant α1(V) collagen chain. Homotrimeric assembly and subsequent processing. *J. Biol. Chem.* 272, 30083–30087, https://doi.org/10.1074/jbc.272.48.30083
14. Birk, D.E. (2001) Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril assembly. *Micron* 32, 223–237, https://doi.org/10.1053/so68-43288000043-3
15. De Paeppe, A., Nuytinck, L., Hauser, I., Anton-Lamprecht, I. and Naeve, J.M. (1997) Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. *Am. J. Hum. Genet.* 60, 547–554
16. Symoens, S., Syx, D., Malfait, F., Callewaert, B., De Backer, J., Vanacker, O. et al. (2012) Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. *Hum. Mutat.* 33, 1485–1493, https://doi.org/10.1002/humu.22137
17. Symoens, S., Malfait, F., Renard, M., Andre, J., Hauser, I., Roeys, B. et al. (2009) COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers–Danlos syndrome. *Hum. Mutat.* 30, 439–440, https://doi.org/10.1002/humu.20887
18. Mitchell, A.L., Schwarze, U., Jennings, J.F. and Byers, P.H. (2009) Molecular mechanisms of classical Ehlers–Danlos syndrome (EDS). *Hum. Mutat.* 30, 995–1002, https://doi.org/10.1002/humu.21000

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
19 Zoppi, N., Gardella, R., De Paepe, A., Barlati, S. and Colombi, M. (2004) Human fibroblasts with mutations in COL5A1 and COL3A1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate alpha2beta1 integrin, and recruit alphavbeta3 instead of alpha5beta1 integrin. J. Biol. Chem. 279, 18157–18168, https://doi.org/10.1074/jbc.M312609200

20 Posthumus, M., September, A.V., O’Cuinneagain, D., van der Merwe, W., Schwellnus, M.P. and Collins, M. (2009) The COL5A1 gene is associated with increased risk of anterior cruciate ligament ruptures in female participants. Am. J. Sports Med. 37, 2234–2240, https://doi.org/10.1177/0363546509338266

21 Niyibizi, C., Kavalkovich, K., Yamaji, T. and Woo, S.L. (2000) Type V collagen is increased during rabbit medial collateral ligament healing. Knee Surg. Sports Traumatol. Arthrosc. 8, 281–285, https://doi.org/10.1007/s001670000134

22 Johnston, J.M., Connizzo, B.K., Shetye, S.S., Robinson, K.A., Huegel, J., Rodriguez, A.B. et al. (2017) Collagen V haploinsufficiency in a murine model of classic Ehlers-Danlos syndrome is associated with deficient structural and mechanical healing in tendons. J. Orthop. Res. 35, 2707–2715, https://doi.org/10.1002/jor.23571

23 Nielsen, R.H., Couppé, C., Jensen, J.K., Olsen, M.R., Heinemeier, K.M., Malfait, F. et al. (2014) Low tendon stiffness and abnormal ultrastructure distinguish classic Ehlers-Danlos syndrome from benign joint hypermobility syndrome in patients. FASEB J. 28, 4668–4676, https://doi.org/10.1096/fj.14-249656

24 Mackenroth, L., Fischer-Zirnsak, B., Egerer, J., Hecht, J., Kallinic, T., Stenzel, W. et al. (2016) An overlapping phenotype of Osteogenesis Imperfecta and Ehlers-Danlos syndrome due to a heterozygous mutation in COL1A1 and biallelic missense variants in TNXB identified by whole exome sequencing. Am. J. Med. Genet. 170A, 1080–1085, https://doi.org/10.1002/ajmg.a.37547